Nikkei Industry Sector
Pharmaceuticals
Overview
Japan's pharmaceutical sector includes both large domestic-focused drug makers and globally operating biopharmaceutical companies with significant international revenue. The industry combines deep scientific capability with strong regulatory relationships and a large aging domestic patient population that drives consistent baseline demand.
Current Trend
Japanese pharma companies are accelerating globalization through overseas acquisitions, licensing deals, and co-development partnerships—particularly in oncology and rare diseases. Biosimilar manufacturing, leveraging Japan's precision production expertise, is also emerging as a significant growth opportunity as biologic patents expire globally.
Companies in This Sector
9
Today's Avg. Price Change
+1.39%
Simple average of constituent stock price changes vs. previous close. Not a sector index.
Updated: 2026-10-30 (JST)
Position in Japan
Japan is the world's third-largest pharmaceutical market by value, providing a stable and substantial home base. The National Health Insurance system, while exerting downward pricing pressure through biennial drug price revisions, ensures broad market access for approved therapies and a predictable revenue floor.
Latest Press Releases
26
May
DAIICHI SANKYO COMPANY,LIMITED JP3475350009
2026-05-25 DAIICHI SANKYO COMPANY,LIMITED “The European Medicines Agency's recommendation for approval of trastuzumab deruxtecan (T-DXd/DS-8201) for multiple HER2-positive solid tumors (260.5KB) will open in a new window.”
26
May
DAIICHI SANKYO COMPANY,LIMITED JP3475350009
2026-05-25 DAIICHI SANKYO COMPANY,LIMITED “The PDF file (311.8KB) regarding the partial amendment approval of Datroway® (datopotamab deruxtecan) for the first-line treatment of triple-negative breast cancer in the United States will open in a new window.”
26
May
CHUGAI PHARMACEUTICAL CO.,LTD. JP3519400000
2026-05-25 CHUGAI PHARMACEUTICAL CO.,LTD. “Organizational changes and personnel announcements.”
23
May
Sumitomo Pharma Co.,Ltd. JP3495000006
2026-05-22 Sumitomo Pharma Co.,Ltd. “Notice Regarding the Results of the Third-Party Allotment of Shares (Not Implemented).”
23
May
Astellas Pharma Inc. JP3942400007
2026-05-22 Astellas Pharma Inc. “The European CHMP has adopted a recommendation for marketing authorization of the antibody-drug conjugate PADCEV™ (enfortumab vedotin) in combination with pembrolizumab for cisplatin-unsuitable resectable muscle-invasive bladder cancer.”
22
May
Eisai Co.,Ltd. JP3160400002
2026-05-21 Eisai Co.,Ltd. “At the American Society of Clinical Oncology (ASCO) Annual Meeting, we presented new data that reinforces the clinical evidence for the approved indications of Lenvima® (lenvatinib).”
20
May
Shionogi & Co.,Ltd. JP3347200002
2026-05-19 Shionogi & Co.,Ltd. “Regarding the positive interim analysis results of the domestic Phase III clinical trial of the aromatic hydrocarbon receptor (AhR) modulator "Tapinarov Cream 0.5%" in infants and young children with atopic dermatitis.”
20
May
Astellas Pharma Inc. JP3942400007
2026-05-19 Astellas Pharma Inc. “At the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting, we will present data on the long-term outcomes and real-world clinical use of our portfolio across all disease stages.”
20
May
Takeda Pharmaceutical Company Limited JP3463000004
2026-05-19 Takeda Pharmaceutical Company Limited “Regarding the jury verdict in the U.S. antitrust lawsuit concerning AMITIZA® (lubiprostone) and the related revision of the financial results for the fiscal year ending March 2026 (FY2025).”
19
May
Otsuka Holdings Co.,Ltd. JP3188220002
2026-05-18 Otsuka Holdings Co.,Ltd. “FACEDUO launches new program "Heatstroke Prevention VR" to allow users to experience the signs of heatstroke and take action to prevent it from occurring or becoming severe in the elderly.”
19
May
DAIICHI SANKYO COMPANY,LIMITED JP3475350009
2026-05-18 DAIICHI SANKYO COMPANY,LIMITED “The PDF file (277.7KB) regarding the approval of two partial changes to the Enhertu® (trastuzumab deruxtecan) drug for HER2-positive early-stage breast cancer in the United States will open in a new window.”
19
May
Eisai Co.,Ltd. JP3160400002
2026-05-18 Eisai Co.,Ltd. “Selected for the first time as one of the "SX Stocks 2026".”
19
May
CHUGAI PHARMACEUTICAL CO.,LTD. JP3519400000
2026-05-18 CHUGAI PHARMACEUTICAL CO.,LTD. “Alecensa has received approval for the world's first cross-organ indication expansion for ALK fusion gene-positive solid tumors in adults and children.”
19
May
CHUGAI PHARMACEUTICAL CO.,LTD. JP3519400000
2026-05-18 CHUGAI PHARMACEUTICAL CO.,LTD. “FoundationOne CDx cancer genome profiling has been approved as a companion diagnostic for Alectinib for ALK fusion gene-positive solid tumors.”
18
May
CHUGAI PHARMACEUTICAL CO.,LTD. JP3519400000
2026-05-18 CHUGAI PHARMACEUTICAL CO.,LTD. “Alecensa has received approval for the world's first cross-organ indication expansion for ALK fusion gene-positive solid tumors in adults and children.”
18
May
CHUGAI PHARMACEUTICAL CO.,LTD. JP3519400000
2026-05-18 CHUGAI PHARMACEUTICAL CO.,LTD. “FoundationOne CDx cancer genome profiling has been approved as a companion diagnostic for Alectinib for ALK fusion gene-positive solid tumors.”
16
May
Eisai Co.,Ltd. JP3160400002
2026-05-15 Eisai Co.,Ltd. “Notice Regarding Disposition of Treasury Stock in Connection with the Continuation of the Stock-Based Compensation Plan (Executive Compensation BIP Trust).”
16
May
Eisai Co.,Ltd. JP3160400002
2026-05-15 Eisai Co.,Ltd. “Notice Regarding the Continuation of the Stock-Based Compensation Plan (Executive Compensation BIP Trust).”
16
May
Shionogi & Co.,Ltd. JP3347200002
2026-05-15 Shionogi & Co.,Ltd. “We have posted the transcript of the FY2025 financial results briefing.”
16
May
Astellas Pharma Inc. JP3942400007
2026-05-15 Astellas Pharma Inc. “Announcement Regarding the Continuation of Performance-Linked Stock Compensation and Performance-Linked Stock Grant Programs for Executives of Our Group Companies in Japan and Overseas.”